EUVIMEDEUVIMED entdecken
Open Access

Evaluation of a Serum Lung Cancer Biomarker Panel

Peter J Mazzone, Xiao-Feng Wang, Xiaozhen Han, Humberto Choi, Meredith Seeley, Richard Scherer, Victoria Doseeva

Biomarker Insights · 01.01.2018 · 13

DOI: 10.1177/1177271917751608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomarker Insights, online erschienen am 15.01.2018. Verfasst von Peter J Mazzone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A panel of 3 serum proteins and 1 autoantibody has been developed to assist with the detection of lung cancer. We aimed to validate the accuracy of the biomarker panel in an independent test set and explore the impact of adding a fourth serum protein to the panel, as well as the impact of combining molecular and clinical variables.

Methods

The training set of serum samples was purchased from commercially available biorepositories. The testing set was from a biorepository at the Cleveland Clinic. All lung cancer and control subjects were >50 years old and had smoked a minimum of 20 pack-years. A panel of biomarkers including CEA (carcinoembryonic antigen), CYFRA21-1 (cytokeratin-19 fragment 21-1), CA125 (carbohydrate antigen 125), HGF (hepatocyte growth factor), and NY-ESO-1 (New York esophageal cancer-1 antibody) was measured using immunoassay techniques. The multiple of the median method, multivariate logistic regression, and random forest modeling was used to analyze the results.

Results

The training set consisted of 604 patient samples (268 with lung cancer and 336 controls) and the testing set of 400 patient samples (155 with lung cancer and 245 controls). With a threshold established from the training set, the sensitivity and specificity of both the 4- and 5-biomarker panels on the testing set was 49% and 96%, respectively. Models built on the testing set using only clinical variables had an area under the receiver operating characteristic curve of 0.68, using the biomarker panel 0.81 and by combining clinical and biomarker variables 0.86.

Conclusions

This study validates the accuracy of a panel of proteins and an autoantibody in a population relevant to lung cancer detection and suggests a benefit to combining clinical features with the biomarker results.

Schlagwörter

Stichwörter der Autor:innen

New York esophageal cancer-1 antibodycarbohydrate antigen 125carcinoembryonic antigencytokeratin-19 fragment 21-1hepatocyte growth factor

Autor:innen und Institutionen

  • Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
  • 20/20 GeneSystems, Rockville, MD, USA.

Zitieren

APA

Mazzone, P. J., Wang, X. F., Han, X., Choi, H., Seeley, M., Scherer, R., & Doseeva, V. (2018). Evaluation of a Serum Lung Cancer Biomarker Panel. Biomarker Insights, 13. https://doi.org/10.1177/1177271917751608

Vancouver

Mazzone PJ, Wang XF, Han X, Choi H, Seeley M, Scherer R, et al. Evaluation of a Serum Lung Cancer Biomarker Panel. Biomarker Insights. 2018;13. doi:10.1177/1177271917751608

BibTeX
@article{Mazzone2018,
  author = {Mazzone, Peter J and Wang, Xiao-Feng and Han, Xiaozhen and Choi, Humberto and Seeley, Meredith and Scherer, Richard and Doseeva, Victoria},
  title = {Evaluation of a Serum Lung Cancer Biomarker Panel},
  journal = {Biomarker Insights},
  year = {2018},
  volume = {13},
  doi = {10.1177/1177271917751608}
}
Kostenlos starten →